文献速递其他结缔组织病

自体造血干细胞移植与联合治疗在进展性系统性硬化症中的结局比较

Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该回顾性研究比较了接受自体造血干细胞移植(AHSCT)的16例早期弥漫性进展性系统性硬化症(SSc)患者与接受MMF联合利妥昔单抗治疗的21例符合AHSCT条件的患者。12个月临床改善率两组相似(联合组86% vs AHSCT组81%,P=0.7),24个月无事件生存的风险比有利于联合组(HR=0.09,P=0.04)。两组mRSS和FVC在各随访时间点至24个月均有显著且相当的改善。

要点

  • 联合组12个月临床改善18例(86%),AHSCT组13例(81%),差异无统计学意义(P=0.7)。
  • 24个月无事件生存的风险比有利于联合组(HR=0.09,P=0.04)。
  • 两组至24个月各时间点mRSS和FVC均显著且相当改善。

核心结论

  • 在符合AHSCT条件的SSc患者中,MMF联合利妥昔单抗与AHSCT相比,24个月时皮肤和肺部临床改善相似,且安全性更好。

研究设计与样本

  • 回顾性比较研究,纳入21例接受MMF联合利妥昔单抗联合治疗的患者与16例接受AHSCT的患者。
  • 重复评估改良Rodnan皮肤评分(mRSS)、用力肺活量(FVC)和弥散功能(DLCO)。
  • 临床改善定义为mRSS下降>25%或FVC增加>10%;无事件生存(EFS)定义为无持续主要器官衰竭或死亡。

主要发现

  • 联合治疗组与AHSCT组年龄、性别和疾病病程相似。
  • 12个月临床改善:联合组18例(86%)vs AHSCT组13例(81%),P=0.7。
  • 24个月EFS的风险比有利于联合组(HR=0.09,P=0.04)。
  • 随访期间两组至24个月各时间点mRSS均显著且相当下降,FVC均显著且相当增加。

关键数值与推荐

  • 临床改善定义为mRSS下降>25%或FVC增加>10%。
  • 无事件生存定义为无持续主要器官衰竭或死亡。
  • AHSCT组16例,联合治疗组21例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Autologous hematopoietic stem cell transplantation (AHSCT) has been shown to improve long-term survival for early diffuse progressive SSc compared with CYC. CYC, however, does not provide a long-term benefit in SSc. The combination of MMF and rituximab is a potent alternative regimen. We aimed to retrospectively compare the outcomes of SSc patients who underwent AHSCT to patients who met the eligibility criteria for AHSCT but received upfront combination therapy with MMF and rituximab. METHODS: Repeated assessments of modified Rodnan Skin Score (mRSS), forced vital capacity (FVC), and diffusing capacity (DLCO) values were conducted. Clinical improvement was defined as an mRSS decrease >25% or an FVC increase >10%. Event-free survival (EFS) was defined in the absence of persistent major organ failure or death. RESULTS: Twenty-one SSc patients in the combination therapy group were compared with 16 in the AHSCT group. Age, sex and disease duration were similar between the two groups. Clinical improvement at 12 months was seen in 18 (86%) patients in the combination group compared with 13 (81%) in the AHSCT group (P = 0.7). The hazard ratio for EFS at 24 months favoured the combination group (HR = 0.09, P = 0.04). During follow-up, both groups exhibited a significant and comparable reduction in mRSS and an increase in FVC values at each time interval up to 24 months. CONCLUSION: MMF and rituximab compared with AHSCT in SSc patients eligible for AHSCT resulted in similar skin and lung clinical improvement with a better safety profile at 24 months.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Keret S, Henig I, Zuckerman T, et al. Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy. Rheumatology (Oxford). 2024. PMID: 37672021. doi:10.1093/rheumatology/kead457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。